FIG 3.

Production of HCMV from cells treated with PI3K-C2A siRNA. HFFs were treated with Ctrl siRNA, PI3K-C2A siRNA, or PI3KC2A-1 to -4 siRNAs and infected with HCMV. (A and B) At the time points (hours postinfection [h.p.i.]) indicated at the top (A) and on the x axis (B), lysates from infected cells treated with PI3K-C2A siRNA were prepared for Western blotting (A) and viral supernatant was titrated to quantify virus produced from siRNA-treated cells (B). The data in panel B are representative of those from two experiments. (C and D) Cells treated with Ctrl or PI3KC2A-1 to -4 siRNAs were infected with HCMV, and the viral supernatants and lysates were harvested at 72 h p.i. Uninfected cell lysate was prepared at the time of infection. Lysates were analyzed by Western blotting (C), and the supernatant was titrated to quantify virus production (D). In panels A and C, proteins recognized by the antibodies used in each experiment are indicated to the right. The positions of molecular mass markers (in kilodaltons) are indicated to the left. In panels B and D, the viral titer is expressed as PFU per milliliter.